Đang chuẩn bị liên kết để tải về tài liệu:
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a reallife setting. |

TÀI LIỆU LIÊN QUAN

Optimal Medical Therapy with or without PCI for Stable Coronary Disease

Towards an optimal therapy strategy for myogenous TMD, physiotherapy compared with occlusal splint therapy in an RCT with therapy-and-patient-specific treatment durations

Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection

Clinical analysis of kasabach-merritt syndrome in 17 neonates

Báo cáo y học: "Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on Antiretroviral Therapy (ART) in sub-Saharan Africa: Frequency and clinical significance"

Báo cáo khoa học: " Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans"

Báo cáo y học: "Optimal vasopressor drug therapy during resuscitation"

Multiple anti-epileptic drug use in children with epilepsy in Mulago hospital, Uganda: A cross sectional study

Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma

Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems